中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
28期
76-78,79
,共4页
脾氨肽%小儿反复呼吸道感染%免疫失衡
脾氨肽%小兒反複呼吸道感染%免疫失衡
비안태%소인반복호흡도감염%면역실형
Spleen aminopeptidase%Recurrent respiratory infections%Immune imbalance
目的:分析探讨脾氨肽(复可托)治疗反复呼吸道感染的临床疗效。方法:选取本院近年来收治的60例反复呼吸道感染患者作为研究对象,按照数字抽签法将其随机分为研究组与对照组,每组30例,研究组在常规治疗的基础上行复可托治疗,对照组仅行常规治疗,比较两组治疗效果。结果:研究组治疗显效率为56.7%,总有效率为90.0%,对照组治疗显效率为23.3%,总有效率为50.0%,研究组患者治疗效果明显优于对照组(P<0.05)。与治疗前相比,研究组患者治疗后CD8指标出现明显下降,CD3、CD4、CD4/CD8指标出现明显上升,治疗前后研究组患者T细胞亚群指标比较差异有统计学意义(P<0.05)。结论:复可托治疗反复呼吸道感染可改善患者免疫失衡状态,具有显著的临床疗效。
目的:分析探討脾氨肽(複可託)治療反複呼吸道感染的臨床療效。方法:選取本院近年來收治的60例反複呼吸道感染患者作為研究對象,按照數字抽籤法將其隨機分為研究組與對照組,每組30例,研究組在常規治療的基礎上行複可託治療,對照組僅行常規治療,比較兩組治療效果。結果:研究組治療顯效率為56.7%,總有效率為90.0%,對照組治療顯效率為23.3%,總有效率為50.0%,研究組患者治療效果明顯優于對照組(P<0.05)。與治療前相比,研究組患者治療後CD8指標齣現明顯下降,CD3、CD4、CD4/CD8指標齣現明顯上升,治療前後研究組患者T細胞亞群指標比較差異有統計學意義(P<0.05)。結論:複可託治療反複呼吸道感染可改善患者免疫失衡狀態,具有顯著的臨床療效。
목적:분석탐토비안태(복가탁)치료반복호흡도감염적림상료효。방법:선취본원근년래수치적60례반복호흡도감염환자작위연구대상,안조수자추첨법장기수궤분위연구조여대조조,매조30례,연구조재상규치료적기출상행복가탁치료,대조조부행상규치료,비교량조치료효과。결과:연구조치료현효솔위56.7%,총유효솔위90.0%,대조조치료현효솔위23.3%,총유효솔위50.0%,연구조환자치료효과명현우우대조조(P<0.05)。여치료전상비,연구조환자치료후CD8지표출현명현하강,CD3、CD4、CD4/CD8지표출현명현상승,치료전후연구조환자T세포아군지표비교차이유통계학의의(P<0.05)。결론:복가탁치료반복호흡도감염가개선환자면역실형상태,구유현저적림상료효。
Objective:To investigate the spleen ammonia peptide(complex)clinical curative effect for the treatment of recurrent respiratory tract infections. Method:To select 60 patients admitted in our hospital in recent years, patients with recurrent respiratory tract infections as the research object,according to the digital lottery method were randomly divided into research group and control group,30 cases in each group,the team in uplink compound could be the basis of routine therapy treatment,the control group only routine treatment,compare therapeutic effect of the two groups. Result:Team treatment efficiency was 56.7%,total effective rate was 90.0%,the control group’s treatment efficiency was 23.3%,total effective rate was 50.0%,the team with the treatment effect was better than the control group (P<0.05). Compared with before treatment,the team CD8 index after treatment in patients with decreased obviously, CD3,CD4,CD4/CD8 indicators appeared obvious rise,before and after treatment group patients with T cell subgroup index comparison difference was statistically significant(P<0.05). Conclusion:Compound can improve the patients' immune treatment of recurrent respiratory tract infections is imbalance,has significant clinical effect.